Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
文献类型：期刊论文
| 作者 | Wang, Zeng2; Jiang, Liyu1; Yan, Hao1; Xu, Zhifei1; Luo, Peihua1 |
| 刊名 | EXPERT REVIEW OF CLINICAL PHARMACOLOGY
 |
| 出版日期 | 2021-03-01 |
| 关键词 | Adverse events chronic myeloid leukemia management mechanisms molecular target nilotinib |
| ISSN号 | 1751-2433 |
| DOI | 10.1080/17512433.2021.1894129 |
| 通讯作者 | Luo, Peihua(xzfzjut@zju.edu.cn) |
| 英文摘要 | Introduction: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients who are resistant or intolerant to prior therapy that includes imatinib. In addition to common adverse reactions, long-term use of nilotinib shows some toxicities that are different from those of occurring during other BCR/ABL TKI treatments, such as cardiovascular toxicity. It is life-threatening, which would affect not only the choice of initial treatment of CML patients but also the safety of long-term medication. Areas covered: Through searching literature and reports from PubMed and clinical trials, here we review a profile of the adverse effects induced by nilotinib. We also discuss the potential molecular toxicological mechanisms and clinical management, which may provide strategies to prevent or intervene the toxicity associated with nilotinib. Expert opinion: Severe adverse effects associated with nilotinib limit its long-term clinical application. However, the exact mechanisms underlying these toxicities remain unclear. Future research should focus on the developing strategies to reduce the toxicities of nilotinib as well as to avoid similar toxicity in the development of new drugs. |
| 资助项目 | National Natural Science Foundation of China[82003862] ; 1022 Talent Training Program of Zhejiang Cancer Hospital |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000624006200001 |
| 出版者 | TAYLOR & FRANCIS LTD |
| 资助机构 | National Natural Science Foundation of China ; 1022 Talent Training Program of Zhejiang Cancer Hospital |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/120958]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Luo, Peihua |
| 作者单位 | 1.Zhejiang Univ, Ctr Drug Safety Evaluat & Res, Coll Pharmaceut Sci, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Canc & Basic Med ICBM, Dept Colorectal Pharm,Canc Hosp,Zhejiang Canc Hos, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Zeng,Jiang, Liyu,Yan, Hao,et al. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY,2021. |
| APA | Wang, Zeng,Jiang, Liyu,Yan, Hao,Xu, Zhifei,&Luo, Peihua.(2021).Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. |
| MLA | Wang, Zeng,et al."Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies".EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。